Access90: Katherine Ka Wan

With the MHRA becoming the standalone regulator of medicines in Great Britain, Precision research aims to shed light on market access in the post-Brexit era, as well as key implications for manufacturers. In this Access90, Precision's Katherine Ka Wan Leong discusses two research posters the PRECISION team will be presenting at ISPOR US this year focusing on the UK access landscape.

LEARN MORE

Access90: Katherine Ka Wan2023-07-12T12:56:50-04:00

On Demand: Cell and Gene Therapies – How High Can Prices Go?

This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).

LEARN MORE

On Demand: Cell and Gene Therapies – How High Can Prices Go?2023-07-18T19:46:57-04:00

Article: The Future of Gene Therapies: Three Trends

Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision's Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.

LEARN MORE

Article: The Future of Gene Therapies: Three Trends2023-06-02T20:02:57-04:00